Artículos por temáticas

Baicalin attenuated substantia nigra neuronal apoptosis in Parkinson's disease rats via the mTOR/AKT/GSK-3β pathway.

Zhai H, Kang Z, Zhang H, Ma J, Chen G.

J Integr Neurosci. 2019 Dec 30;18(4):423-429. doi: 10.31083/j.jin.2019.04.192.

Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis

Devos D, Cabantchik ZI, Moreau C, Danel V, Mahoney-Sanchez L, Bouchaoui H, Gouel F, Rolland AS, Duce JA, Devedjian JC; FAIRPARK-II and FAIRALS-II studygroups.

J Neural Transm (Vienna). 2020 Feb;127(2):189-203. doi: 10.1007/s00702-019-02138-1. Epub 2020 Jan 7.

Replacing what's lost: a new era of stem cell therapy for Parkinson's disease

Fan Y, Winanto, Ng SY.

Transl Neurodegener. 2020 Jan 7;9:2. doi: 10.1186/s40035-019-0180-x. eCollection 2020.

The drug adaptaquin blocks ATF4/CHOP-dependent pro-death Trib3 induction and protects in cellular and mouse models of Parkinson's disease

Aimé P, Karuppagounder SS, Rao A, Chen Y, Burke RE, Ratan RR, Greene LA.

Neurobiol Dis. 2020 Mar;136:104725. doi: 10.1016/j.nbd.2019.104725. Epub 2020 Jan 3.

What drugs modify the risk of iatrogenic impulse-control disorders in Parkinson's disease? A preliminary pharmacoepidemiologic study

Jeon N, Bortolato M.

PLoS One. 2020 Jan 7;15(1):e0227128. doi: 10.1371/journal.pone.0227128. eCollection 2020.

Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease

de Faria SM, de Morais Fabrício D, Tumas V, Castro PC, Ponti MA, Hallak JE, Zuardi AW, Crippa JAS, Chagas MHN.

J Psychopharmacol. 2020 Feb;34(2):189-196. doi: 10.1177/0269881119895536. Epub 2020 Jan 7.

Generation of a Novel Mouse Model of Parkinson's Disease via Targeted Knockdown of Glutamate Transporter GLT-1 in the Substantia Nigra

Zhang Y, Meng X, Jiao Z, Liu Y, Zhang X, Qu S.

ACS Chem Neurosci. 2020 Feb 5;11(3):406-417. doi: 10.1021/acschemneuro.9b00609. Epub 2020 Jan 21.

Topological changes in white matter connectivity network in patients with Parkinson's disease and depression

Hu X, Qian L, Zhang Y, Xu Y, Zheng L, Liu Y, Zhang X, Zhang Y, Liu W.

Brain Imaging Behav. 2020 Dec;14(6):2559-2568. doi: 10.1007/s11682-019-00208-2.

Parkinson's disease: proteinopathy or lipidopathy?

Fanning S, Selkoe D, Dettmer U.

NPJ Parkinsons Dis. 2020 Jan 3;6:3. doi: 10.1038/s41531-019-0103-7. eCollection 2020.

[Current Status and Future Prospects of Therapeutic Development of Parkinson's Disease]

Mochizuki H.

Brain Nerve. 2020 Jan;72(1):35-43. doi: 10.11477/mf.1416201476.

[Application of intracranial lead reconstruction in deep brain stimulation therapy in patients with Parkinson's disease].

Zheng X, Yu L, Wan X, Wang H, Yu T, He Q, Lin Z, Kang D.

Nan Fang Yi Ke Da Xue Xue Bao. 2019 Dec 30;39(12):1461-1468. doi: 10.12122/j.issn.1673-4254.2019.12.10. Chinese.

L-DOPA in Parkinson's Disease: Looking at the "False" Neurotransmitters and Their Meaning.

Chagraoui A, Boulain M, Juvin L, Anouar Y, Barrière G, Deurwaerdère P.

Int J Mol Sci. 2019 Dec 31;21(1). pii: E294. doi: 10.3390/ijms21010294. Review.

Celastrol Inhibits Dopaminergic Neuronal Death of Parkinson's Disease through Activating Mitophagy.

Lin MW, Lin CC, Chen YH, Yang HB, Hung SY.

Antioxidants (Basel). 2019 Dec 31;9(1). pii: E37. doi: 10.3390/antiox9010037.

A Multimodal Approach to the Quantification of Kinetic Tremor in Parkinson's Disease.

Szumilas M, Lewenstein K, Ślubowska E, Szlufik S, Koziorowski D.

Sensors (Basel). 2019 Dec 28;20(1). pii: E184. doi: 10.3390/s20010184.

In Vivo Mitochondrial Function in Idiopathic and Genetic Parkinson's Disease.

Dossi G, Squarcina L, Rango M.

Metabolites. 2019 Dec 28;10(1). pii: E19. doi: 10.3390/metabo10010019. Review.